The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 146-150

  Matesanz, Fuencisla ^a   Fernández, Oscar ^b   Milne, Roger L ^c   Fedetz, Maria ^a   Leyva, Laura ^b   Guerrero, Miguel ^d   Delgado, Concepción ^e   Lucas, Miguel ^f   Izquierdo, Guillermo ^f   Alcina, Antonio ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e Centro Regional de Transfusión Sanguínea Granada Almería   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

FCRL3; Genetic factor; Multiple sclerosis; Polymorphisms; SNP

Indexed keywords

ARTICLE; CONTROLLED STUDY; FCRL3 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ASPARAGINE; ASPARTIC ACID; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; SPAIN; STATISTICS, NONPARAMETRIC;

EID: 41949123283     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.01.004     Document Type: Article

References (28)

1. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
2. Becker T., and Knapp M. Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet. Epidemiol. 27 (2004) 21-32
3. Capon F., Semprini S., Chimenti S., Fabrizi G., Zambruno G., Murgia S., Carcassi C., Fazio M., Mingarelli R., Dallapiccola B., and Novelli G. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J. Invest. Dermatol. 116 (2001) 728-730
4. Comi C., Leone M., Bonissoni S., DeFranco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., and Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 55 (2000) 921-927
5. Dai K.Z., Harbo H.F., Celius E.G., Oturai A., Sorensen P.S., Ryder L.P., et al. The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes Immun. 2 (2001) 263-268
6. Dyment D.A., Ebers G.C., and Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol. 3 (2004) 104-110
7. Fedetz M., Matesanz F., Caro-Maldonado A., Fernandez O., Tamayo J.A., Guerrero M., et al. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 68 (2006) 446-449
8. Fernández O., Luque G., San Roman C., Bravo M., and Dean G. The prevalence of multiple sclerosis in the Sanitary District of Vélez-Málaga, southern Spain. Neurology 44 (1994) 425-429
9. Hu X., Chang M., Saiki R.K., Cargill M.A., Begovich A.B., Ardlie K.G., et al. The functional - 169T → C single-nucleotide polymorphism in FCRL3 is not associated with rheumatoid arthritis in white North Americans. Arthritis Rheum. 54 (2006) 1022-1025
10. Ikari K., Momohara S., Nakamura T., Hara M., Yamanaka H., Tomatsu T., and Kamatani N. Supportive evidence for a genetic association of the FCRL3 promoter polymorphism with rheumatoid arthritis. Ann. Rheum. Dis. 65 (2006) 671-673
11. Kantarci, O.H., Weinshenker, B.G. "Multiple sclerosis" pp 289-304. In Cytokine gene polymorphisms in multifactorial conditions. Edited by Koen Vandenbroeck. CRC presss, Taylor and Francis group 2006.
12. Kochi Y., Yamada R., Suzuki A., Harley J.B., Shirasawa S., Sawada T., et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet. 37 (2005) 478-485
13. Leyva L., Fernandez O., Fedetz M., Blanco E., Fernandez V.E., Oliver B., et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J. Neuroimmunol. 163 (2005) 165-171
14. Lucchinetti C.F., Bruck W., and Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 56 (2004) 308
15. Martínez A., Sanchez E., Valdivia A., Orozco G., Lopez-Nevot M.A., Pascual-Salcedo D., et al. Epistatic interaction between FCRL3 and NFkappaB1 genes in Spanish patients with rheumatoid arthritis. Ann. Rheum. Dis. 65 (2006) 1188-1191
16. Martínez A., Mas A., De las Heras V., Bartolomé M., Arroyo R., Fernández-Arquero M., et al. FcRL3 and multiple sclerosis pathogenesis: role in autoimmunity?. J. Neuroimmunol. 189 (2007) 132-136
17. Matesanz F., Fedetz M., Leyva L., Delgado C., Fernández O., and Alcina A. Effects of the multiple sclerosis associated - 330 promoter polymorphism in IL2 allelic expression. J. Neuroimmunol. 148 (2004) 212-217
18. Newman W.G., Zhang Q., Liu X., Walker E., Ternan H., Owen J., et al. Rheumatoid arthritis association with the FCRL3 - 169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population. Arthritis Rheum. 54 (2006) 3820-3827
19. Owen C.J., Kelly H., Eden J.A., Merriman M.E., Pearce S.H., and Merriman T.R. Analysis of the Fc-receptor like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association. J. Clin. Endocrinol. Metab. 92 (2007) 1106-1111
20. Pittock S.J., Reindl M., Achenbach S., Berger T., Bruck W., Konig F., et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult. Scler. 13 (2007) 7-16
21. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
22. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19 (2001) 275-290
23. Simmonds M.J., Heward J.M., Carr-Smith J., Foxall H., Franklyn J.A., and Gough S.C. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease. J. Clin. Endocrinol. Metab. 91 (2006) 1056-1061
24. Smyth D.J., Howson J.M., Payne F., Maier L.M., Bailey R., Holland K., et al. Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med. Genet. 7 (2006) 20-31
25. Steinman L., Martin R., Bernard C., Conlon P., and Oksenberg J.R. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 25 (2002) 491-505
26. Thabet M.M., Wesoly J., Slagboom P.E., Toes R.E., and Huizinga T.W. FCRL3 promoter 169 CC homozygosity is associated with susceptibility to rheumatoid arthritis in Dutch Caucasians. Ann. Rheum. Dis. 66 (2007) 803-806
27. Turunen J.A., Wessman M., Kilpikari R., Parkkonen M., Forsblom C., Groop P.H., and FinnDiane Study Group. The functional variant - 169C/T in the FCRL3 gene does not increase susceptibility to Type 1 diabetes. Diabet. Med. 23 (2006) 925-927
28. Vandenbroeck K., and Goris A. Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?. Trends Pharmacol. Sci. 24 (2003) 284-289